Surgery (partial or gross total resection or biopsy) must be performed >= 2 weeks prior to registration; patient must have recovered adequately from the effects of surgery
Patients must not have had major surgery within 6 weeks prior to enrollment on the high risk stratum; patients with history of recent minor surgical procedures (vascular catheter placement, bone marrow evaluation, laparoscopic surgery, liver tumor biopsy) will be eligible
Patients should not be randomized less than 3 weeks post-surgery but will not be acceptable for randomization more than 8 weeks post-surgery
Lumbar CSF must be obtained prior to study enrollment unless medically contraindicated; if a patient undergoes surgery and lumbar CSF cannot be obtained at this time, then it should be performed at least 10 days following surgery before study enrollment; false positive cytology can occur within 10 days of surgery; Note: patients with positive CSF cytology obtained prior to 10 days after surgery may have cytology repeated to determine eligibility
Patient must consent for the appropriate surgery
Patients may have received prior surgery (for both the primary and stage IV disease); all adverse events associated with prior surgery must have resolved to =< grade 1 prior to registration
Recent major surgery within a minimum of 4 weeks prior to starting study treatment, with the exception of surgical placement for vascular access
Major surgery within 4 weeks prior to entry into the study, or a surgical incision that is not fully healed
Patients who have received any cytotoxic therapy, immunotherapy, antitumor vaccines, monoclonal antibodies or major surgery in the 4 weeks prior to the start of the study
No major surgery within 28 days prior to registration
Have surgery planned within 3 months of consent; patients who have previously received surgery are eligible
Patients who are not currently candidates for radical cystectomy (e.g. patient refuses surgery, comorbidities preclude major surgery, etc.)
No history of major surgery =< 14 days prior to registration
No history of major surgery =< 28 days of registration
At least 4 weeks must have elapsed since the patient underwent any major surgery (eg. MAJOR: laparotomy, laparoscopy, thoracotomy, VATS [video assisted thorascopic surgery]); there is no restriction on MINOR procedures: (eg. central venous catheter placement, ureteral stent placement or exchange, tumor core or fine-needle aspirate [FNA] biopsy)
Major surgery within 2 weeks prior to randomization: patients must have recovered from any effects of any major surgery
No major surgery =< 14 days prior to registration
Patients must not have received any major surgery or immunotherapy within 28 days prior to registration
The minimum time requirement between date of surgery and randomization must be at least 4 weeks (28 days)
Ibrutinib must be discontinued 7 days before (when possible) until 7 days after major surgery, and 3 days before (when possible) until 3 days after minor surgery; thus, patients to be enrolled on an ibrutinib trial must have completed major surgery > 7 days before initiating treatment, and/or must have completed minor surgery > 3 days before initiating treatment
Major surgery within 4 weeks of first dose of study drug
Patients who are less than 4 weeks post-operative (op) after major surgery
Patients must not have had major surgery within 28 days prior to registration or be scheduled for surgery during the projected course of protocol treatment; tumor biopsy is allowed
No major surgery within 21 days of registration with stabilization or resolution of surgical adverse events
Have had recent major surgery within a minimum of 4 weeks prior to starting study treatment, with the exception of surgical placement for vascular access
No major surgery =< 7 days prior to registration and no minor surgery =< 3 days prior to registration (with the exception of intravenous access placement, e.g. Hickman or peripherally inserted central catheter [PICC])
Major surgery within 21 days of starting protocol treatment
Major surgery within 21 days of starting protocol treatment
Major surgery within 30 days prior or during the study period
Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
Patients may have received prior surgery; at least 28 days must have elapsed since surgery and patient must have recovered from any adverse effects of surgery
Ibrutinib should be held at least 3 to 7 days pre- and post-surgery, depending upon the type of surgery and risk of bleeding
At least 4 weeks since major surgery or radiation therapy
Inability to safely delay surgery by 8 weeks as per surgeons discretion
No prior bariatric surgery or planning to undergo this procedure within the next 2 years after study registration
PRIOR/CONCURRENT THERAPY CRITERIA: Patients must not have had a major surgery within 28 days prior to registration; patients must have recovered from any adverse effects of prior surgery to the satisfaction of the treating physician; biopsies and central IV access placement are not considered major surgery
Patients must be enrolled on ALTE07C1 prior to enrollment on ACNS1422* Patients must be enrolled within 36 days of definitive diagnostic surgery (day 0)** Note: patients must begin treatment within 36 days of definitive surgery
Patients who are not candidates for major abdominal surgery due to known medical comorbidities
Major surgery within 4 weeks before randomization
Patients must have recovered from effects of recent surgery, radiotherapy, or chemotherapy; at least 4 weeks must have elapsed since the patient underwent any major surgery (e.g., major: laparotomy, laparoscopy); there is no delay required for minor procedures (e.g., tumor fine-needle aspiration [FNA] or core biopsy, venous access device placement)
No major surgery within 28 days prior to randomization
Have had recent major surgery within a minimum of 4 weeks prior to starting study treatment, with the exception of surgical placement for vascular access
Patients must NOT have radiotherapy, or major surgery or active drug therapy for pNET (SSA permitted) within 4 weeks prior to study treatment start
Patients who have had major surgery or trauma within 28 days prior to entering the study; patients must have recovered from any effects of any major surgery and surgical wound should have healed prior to starting treatment
Step 1 registration must occur within 180 days of the initial surgery; within this 180 day interval, a second surgery is permitted in order to achieve GTR, but even with a second surgery, step 1 registration must occur within 180 days of the initial resection
Major surgery must not have occurred within 2 weeks prior to enrollment and patients must have recovered from any effects of any major surgery